To date, much of the clinical research on psychedelics has focused on their potential to treat acute mental health conditions, such as treatment-resistant depression. But scientists are also examining the drugs’ effects on so-called “healthy normal” populations — in other words, people who haven’t been diagnosed with an addiction or mental illness. In one 2018…
A healthcare investment firm that’s backing studies of “magic mushrooms” to treat depression raised $25m of capital… …already in talks with banks about a potential listing in Canada next year, a step for which it seeks a valuation of $800m or more, according to one of the people familiar with the matter. After being shunned…
The relative safety of magic mushrooms, when compared to other drugs, is incredibly high. Psilocybin comes in last place when you rank drugs in terms of their harm to the individual or society at large. He also explained that the abuse potential for psilocybin is low. “No one is jonesing for their next [dose of]…
“While psychedelic drugs rose to prominence in the 1960s, the attendees at an Ashland conference say the nation and world would be a better place if the non-addictive drugs regained their footing in society.” The “peace and love” message of the ’60s — inspired in part by psychedelic drugs — hasn’t changed over the last…
Recent Comments